Silicon Valley medical technology firm TibaRay has officially moved its Galactica radiotherapy system into the manufacturing phase, marking a shift from research to clinical deployment. The platform, which utilizes accelerator technology developed at Stanford University, is designed to modernize cancer treatment by reducing the physical footprint and complexity of traditional medical linear accelerators, according to the company.
Modernizing Radiotherapy Infrastructure
For nearly 70 years, radiation oncology has relied on large, stationary linear accelerators that often require significant clinical space and infrastructure. TibaRay CEO Thinh Tran stated that the company’s focus remains on solving the core challenges of precision and accessibility. By moving Galactica into production, the firm aims to replace aging hardware with a more efficient, compact system.
Did you know?
Nearly two-thirds of cancer patients receive radiation therapy as part of their treatment plan. Despite this high demand, many facilities still utilize equipment based on decades-old engineering designs.
Upright Treatment and Patient Comfort
A key differentiator for the Galactica system is its integration with Leo Cancer Care’s upright radiotherapy platform. Unlike traditional systems that require patients to lie in a supine position, this setup allows for treatment while sitting or standing. This design shift is intended to improve patient comfort while maintaining the high levels of precision required for effective radiation delivery. According to TibaRay, the first of these systems is scheduled for installation at the Mayo Clinic later this year.
The Future of FLASH Radiotherapy
Beyond current clinical applications, TibaRay is positioning the Galactica platform as the foundation for future FLASH radiotherapy. This emerging approach aims to deliver radiation in a fraction of a second—a speed researchers believe could eradicate tumors while significantly minimizing damage to surrounding healthy tissue. While still in the development phase, the manufacturing of the Galactica hardware is a prerequisite for moving FLASH technology toward real-world use.
Industry Impact and Clinical Accessibility
The transition to manufacturing represents a broader strategy to make advanced oncology tools more accessible globally. By reducing the size and complexity of radiotherapy equipment, TibaRay aims to lower the barriers that often prevent smaller clinics from offering high-end radiation services. The company expects the platform to serve as a versatile tool for physicians, supporting both standard radiotherapy and future, faster treatment modalities.
Pro Tip: Tracking Medical Innovation
To stay updated on the clinical deployment of the Galactica system and other emerging radiotherapy technologies, follow clinical trial registries and institutional announcements from major research centers like the Mayo Clinic, which often serve as the first sites for new medical hardware implementation.
Frequently Asked Questions
- What is the primary benefit of the Galactica system?
The Galactica system is designed to be smaller, more efficient, and more precise than traditional linear accelerators, allowing for treatment in both upright and standard positions. - When will the first Galactica system be installed?
TibaRay plans to complete its first installation at the Mayo Clinic later this year. - What is FLASH radiotherapy?
FLASH is an experimental treatment approach that delivers radiation in a fraction of a second, potentially reducing side effects by limiting exposure to surrounding healthy tissue.
Are you interested in the intersection of engineering and oncology? Subscribe to our newsletter for the latest updates on medical technology breakthroughs or leave a comment below to share your perspective on the future of cancer treatment.
Worth a look